Bridgefront Capital LLC Makes New Investment in Repligen Co. (NASDAQ:RGEN)

Bridgefront Capital LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,904 shares of the biotechnology company’s stock, valued at approximately $562,000.

A number of other hedge funds also recently made changes to their positions in the stock. Tidal Investments LLC lifted its stake in Repligen by 142.8% during the third quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 6,558 shares during the last quarter. Franklin Resources Inc. boosted its stake in Repligen by 8.7% in the third quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company’s stock worth $47,551,000 after buying an additional 26,668 shares in the last quarter. GAMMA Investing LLC grew its position in Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 90 shares during the last quarter. Everence Capital Management Inc. purchased a new position in shares of Repligen during the fourth quarter worth approximately $294,000. Finally, Diversified Trust Co lifted its holdings in shares of Repligen by 16.9% in the 4th quarter. Diversified Trust Co now owns 12,238 shares of the biotechnology company’s stock worth $1,762,000 after acquiring an additional 1,769 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

Shares of RGEN opened at $140.92 on Tuesday. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The company has a 50-day simple moving average of $137.38 and a two-hundred day simple moving average of $145.84. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $7.91 billion, a PE ratio of -276.31, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm’s revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. On average, analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Royal Bank of Canada decreased their target price on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 30th. Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective on the stock. Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 target price for the company in a report on Tuesday, April 29th. JPMorgan Chase & Co. decreased their price target on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Finally, Canaccord Genuity Group cut their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a report on Wednesday, April 16th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $173.25.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax acquired 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.